JOAN TADDEI: Open Payments
NPI 1760148381 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,791 in 130 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $1,693 · 2025 $2,791
Food & beverage: $2,791
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $328 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $325 |
| PFIZER INC. | 12 | $306 |
| ABBVIE INC. | 18 | $280 |
| Madrigal Pharmaceuticals | 13 | $249 |
| Janssen Biotech, Inc. | 8 | $248 |
| Ardelyx, Inc. | 10 | $206 |
| QOL Medical, LLC | 10 | $162 |
| Aimmune Therapeutics, Inc. | 4 | $110 |
| GENZYME CORPORATION | 5 | $96 |
Products named: XIFAXAN, REZDIFFRA, TREMFYA, ENTYVIO, IBSRELA, RINVOQ, Sucraid, XELJANZ.
Industry payments across DE — which companies pay providers there.
